Based on mucosal immunization to promote both mucosal and systemic immune responses,
next-generation coronavirus disease 2019 (COVID-19) vaccines would be administered …

Historically, annual rotavirus activity in the United States has started in the southwest in late
fall and ended in the northeast 3 months later; this trend has diminished in recent years …

Background We assessed vaccine effectiveness (VE) for RotaTeq (RV5; 3 doses) and
Rotarix (RV1; 2 doses) at reducing rotavirus acute gastroenteritis (AGE) inpatient and …

Background Understanding the safety of vaccines is critical to inform decisions about
vaccination. Our objective was to conduct a systematic review of the safety of vaccines …

Abstract Background. In a Latin American trial, a monovalent G1P rotavirus vaccine showed
high efficacy against severe rotavirus diarrhea. Protection was lower against serotypically …

Rotavirus is the most common cause of fatal and severe childhood diarrhoea worldwide.
Two new rotavirus vaccines have shown efficacy against severe rotavirus disease in large …

Selected topics in the field of rotavirus immunity are reviewed focusing on recent
developments that may improve efficacy and safety of current and future vaccines …

Background The effectiveness of the rotavirus vaccine under conditions of routine use in an
African setting with a high prevalence of HIV infection needs to be established. We assessed …

The mention, or photographic illustration, of specific companies or of certain manufacturers'
products does not imply that they are endorsed or recommended by the World Health …

Rotavirus is responsible for more than half a million deaths among infants and young
children worldwide each year; many of these deaths could be prevented by widespread use …